TY  - JOUR
AU  - Müller, Daniel J
AU  - Freitag, Christine M
AU  - Heilbronner, Urs
AU  - Nöthen, Markus M
AU  - Perneczky, Robert
AU  - Rietschel, Marcella
AU  - Schulte, Eva C
AU  - Deckert, Jürgen
TI  - Genetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit  -  Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease
JO  - Der Nervenarzt
VL  - 97
IS  - 1
SN  - 0028-2804
CY  - Heidelberg
PB  - Springer
M1  - DZNE-2026-00075
SP  - 82 - 85
PY  - 2026
AB  - The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.
KW  - Alzheimer Disease: genetics
KW  - Alzheimer Disease: drug therapy
KW  - Alzheimer Disease: diagnosis
KW  - Humans
KW  - Antibodies, Monoclonal, Humanized: therapeutic use
KW  - Antibodies, Monoclonal, Humanized: adverse effects
KW  - Genetic Testing: methods
KW  - Genetic Predisposition to Disease: genetics
KW  - Apolipoproteins E: genetics
KW  - ApoE-genotype (Other)
KW  - Adverse effects (Other)
KW  - Alzheimer disease (Other)
KW  - Lecanemab (Other)
KW  - Medication safety (Other)
KW  - Antibodies, Monoclonal, Humanized (NLM Chemicals)
KW  - Apolipoproteins E (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40548968
DO  - DOI:10.1007/s00115-025-01839-1
UR  - https://pub.dzne.de/record/284032
ER  -